Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Wolfe Research Continues to Favor Moderna's (MRNA) 'Significiant Upside Optionality' in its Broad Pipeline
May 4, 2022 10:22 AM EDTWolfe Research analyst Andrew Galler reiterated an Outperform rating and $261.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "At the time of our initiation in November 2021, the stock was coming off of a onetwo punch from a cut to COVID vaccine guidance and PFEs topline data for Paxlovid from the EPIC-HR study, but with increasing visibility into the booster opportunity (which has only been helped by the spread of the Omicron variant), the... More
Moderna (MRNA) Tops Q1 EPS by $3.37, Revenue Beats
May 4, 2022 6:54 AM EDTModerna (NASDAQ: MRNA) reported Q1 EPS of $8.58, $3.37 better than the analyst estimate of $5.21. Revenue for the quarter came in at $6.1 billion versus the consensus estimate of $4.62 billion.
For earnings history and earnings-related data on Moderna (MRNA) click here.
... More